运动在代谢相关脂肪性肝病管理中的作用：美国运动医学会和澳大利亚运动与体育科学学会国际专家共识解读

doi:10.12114/j.issn.1007-9572.2025.0359

中国全科医学 ›› 2026, Vol. 29 ›› Issue (23): 3253-3260.DOI: 10.12114/j.issn.1007-9572.2025.0359

• 专题研究·代谢相关脂肪性肝病 • 上一篇下一篇

运动在代谢相关脂肪性肝病管理中的作用：美国运动医学会和澳大利亚运动与体育科学学会国际专家共识解读

许坤¹, 程经纬¹^,^*(), 王聪帅¹, 王银浩¹, 胡俊鹏², 李弯月³, 柳杨青⁴, 席艳⁵

1．475000　河南省开封市，河南大学体育学院
2．450003　河南省郑州市，河南省中医院　河南中医药大学第二附属医院内分泌科
3．450003　河南省郑州市，河南省人民医院　郑州大学人民医院康复科
4．450003　河南省郑州市，河南省人民医院　郑州大学人民医院编辑部
5．475000　河南省开封市，河南大学基础医学院

收稿日期:2025-09-03 修回日期:2025-12-10 出版日期:2026-08-15 发布日期:2026-07-03
通讯作者: 程经纬
许坤和程经纬为共同第一作者

作者贡献：
许坤负责研究构思与设计、论文起草与撰写；王聪帅、王银浩负责论文研究资料的收集与整理；胡俊鹏、李弯月负责论文知识性审查与学术指导；柳杨青负责论文修订；席艳负责研究过程的监督管理；程经纬负责论文的质量控制及审校、对论文整体负责。
基金资助:
河南省重点研发专项(241112310500)

The Role of Exercise in the Management of Metabolic-associated Fatty Liver Disease: Interpretation of the International Expert Consensus of ACSM and ESSA

XU Kun¹, CHENG Jingwei¹^,^*(), WANG Congshuai¹, WANG Yinhao¹, HU Junpeng², LI Wanyue³, LIU Yangqing⁴, XI Yan⁵

1. School of Physical Education, Henan University, Kaifeng 475000, China
2. Department of Endocrinology, Henan Province Hospital of TCM/The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450003, China
3. Department of Rehabilitation, Henan Provincial People's Hospital/Zhengzhou University People's Hospital, Zhengzhou 450003, China
4. Editorial Department, Henan Provincial People's Hospital/Zhengzhou University People's Hospital, Zhengzhou 450003, China
5. School of Basic Medical Sciences, Henan University, Kaifeng 475000, China

Received:2025-09-03 Revised:2025-12-10 Published:2026-08-15 Online:2026-07-03
Contact: CHENG Jingwei
About author:
XU Kun and CHENG Jingwei are co-first authors

摘要/Abstract

摘要： 运动是代谢相关脂肪性肝病（MAFLD）管理的基石，也是逆转肝脂肪变性、降低心血管疾病风险的核心手段。目前尚无监管机构批准的有效治疗药物，因此MAFLD患者需要更精准的运动处方指导。然而，目前针对MAFLD患者的运动指南相对较少。近两年美国运动医学会（ACSM）和澳大利亚运动与体育科学学会（ESSA）分别发布了关于MAFLD患者运动指导建议的专家共识——《ACSM国际多学科圆桌会议关于体育活动和非酒精性脂肪肝的报告》和《运动在成年人代谢相关脂肪性肝病（MAFLD）管理中的作用：ESSA的立场声明》，从运动改善肝脂肪变性的机制、不同运动类型对MAFLD的影响、运动对MAFLD患者的益处、运动处方制定等角度全面提出了指导意见。本文对专家共识的主要内容进行解读，旨在为国内MAFLD患者提供更科学的运动指导。

Abstract:

Exercise is the cornerstone of metabolic-associated fatty liver disease(MAFLD) management and a core approach to reversing hepatic steatosis and reducing cardiovascular risk. Currently, there are no effective therapeutic drugs approved by regulatory authorities for MAFLD, thus patients with MAFLD need more precise exercise prescription guidance. However, there are relatively few exercise guidelines specifically for MAFLD patients at present. With the continuous exploration of this field by experts and scholars, in the past two years, American College of Sports Medicine (ACSM) and Exercise and Sport Science Australia (ESSA) respectively released expert consensuses on exercise guidance recommendations for patients with MAFLD: American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable Report on Physical Activity and Nonalcoholic Fatty Liver Disease and Exercise in the Management of Metabolic-associated Fatty Liver Disease (MAFLD) in Adults: a Position Statement from Exercise and Sport Science Australia. These two expert consensuses comprehensively put forward guiding opinions from the perspectives of the mechanism by which exercise improves hepatic steatosis, the impact of different types of exercise on MAFLD, the benefits of exercise for MAFLD patients, and the formulation of exercise prescriptions. This article interpreted the main contents of the expert consensus, aiming to provide more scientific exercise guidance for domestic MAFLD patients.

Key words: Metabolic-associated fatty liver disease, Physical activity, Exercise prescriptions, American College of Sports Medicine, Exercise and Sport Science Australia, Guideline interpretation

中图分类号:

R 575.5

许坤,程经纬,王聪帅,等. 运动在代谢相关脂肪性肝病管理中的作用：美国运动医学会和澳大利亚运动与体育科学学会国际专家共识解读[J]. 中国全科医学, 2026, 29(23): 3253-3260. DOI: 10.12114/j.issn.1007-9572.2025.0359.
XU Kun,CHENG Jingwei,WANG Congshuai, et al. The Role of Exercise in the Management of Metabolic-associated Fatty Liver Disease: Interpretation of the International Expert Consensus of ACSM and ESSA[J]. Chinese General Practice, 2026, 29(23): 3253-3260. DOI: 10.12114/j.issn.1007-9572.2025.0359.

图/表 3

图1 MAFLD诊断流程图[4]注：1 mmHg=0.133 kPa。

Figure 1 Diagnostic flowchart for MAFLD

图2 运动改善肝脂肪变性的可能机制[4]

Figure 2 Possible mechanisms of the effect of exercise on liver steatosis

图3 运动对MAFLD患者的益处[3]

Figure 3 Benefits of exercise for patients with MAFLD

参考文献 43

[1]	Le M H, Yeo Y H, Li X H, et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2022, 20(12): 2809-2817.e28. DOI: 10.1016/j.cgh.2021.12.002.
[2]	中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J].中华肝脏病杂志, 2024, 32(5): 418-434. DOI: 10.3760/cma.j.cn501113-20240327-00163.
[3]	Stine J G, Long M T, Corey K E, et al. American College of Sports Medicine(ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease[J]. Hepatol Commun, 2023, 7(4): e0108. DOI: 10.1097/HC9.0000000000000108.
[4]	Keating S E, Sabag A, Hallsworth K, et al. Exercise in the management of metabolic-associated fatty liver disease(MAFLD)in adults: a position statement from Exercise and Sport Science Australia[J]. Sports Med, 2023, 53(12): 2347-2371. DOI: 10.1007/s40279-023-01918-w.
[5]	European Association for the Study of the Liver(EASL), European Association for the Study of Diabetes(EASD), European Association for the Study of Obesity(EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol, 2016, 64(6): 1388-1402. DOI: 10.1016/j.jhep.2015.11.004.
[6]	Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367.
[7]	Caspersen C J, Powell K E, Christenson G M. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research[J]. Public Health Rep, 1985, 100(2): 126-131.
[8]	国家卫生健康委, 全国爱卫办, 教育部, 等.关于印发"体重管理年"活动实施方案的通知[J].中华人民共和国国家卫生健康委员会公报, 2024, 6: 6-9.
[9]	Eslam M, Newsome P N, Sarin S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[10]	Gastaldelli A, Natali A, Vettor R, et al. Insulin resistance, adipose depots and gut: interactions and pathological implications[J]. Dig Liver Dis, 2010, 42(5): 310-319. DOI: 10.1016/j.dld.2010.01.013.
[11]	Donnelly K L, Smith C I, Schwarzenberg S J, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease[J]. J Clin Invest, 2005, 115(5): 1343-1351. DOI: 10.1172/JCI23621.
[12]	Rector R S, Thyfault J P, Morris R T, et al. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats[J]. Am J Physiol Gastrointest Liver Physiol, 2008, 294(3): G619-G626. DOI: 10.1152/ajpgi.00428.2007.
[13]	Richter E A, Ruderman N B. AMPK and the biochemistry of exercise: implications for human health and disease[J]. Biochem J, 2009, 418(2): 261-275. DOI: 10.1042/BJ20082055.
[14]	Cusi K, Alkhouri N, Harrison S A, et al. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease(STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study[J]. Lancet Gastroenterol Hepatol, 2021, 6(11): 889-902.
[15]	Diniz T A, De Lima Junior E A, Teixeira A A, et al. Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-α signaling in obese mice[J]. Life Sci, 2021, 266: 118868.
[16]	Stine J G. Editorial: twenty minutes of moderate-to-vigorous physical activity a day keeps the NAFLD away[J]. Aliment Pharmacol Ther, 2022, 55(1): 116-117. DOI: 10.1111/apt.16662.
[17]	Tsunoda K, Kitano N, Kai Y, et al. Dose-response relationships of accelerometer-measured sedentary behaviour and physical activity with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2021, 54(10): 1330-1339. DOI: 10.1111/apt.16631.
[18]	Johnson N A, Sachinwalla T, Walton D W, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss[J]. Hepatology, 2009, 50(4): 1105-1112.
[19]	O'Gorman P, Naimimohasses S, Monaghan A, et al. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention[J]. Aliment Pharmacol Ther, 2020, 52(8): 1387-1398. DOI: 10.1111/apt.15989.
[20]	Hughes A, Dahmus J, Rivas G, et al. Exercise training reverses gut dysbiosis in patients with biopsy-proven nonalcoholic steatohepatitis: a proof of concept study[J]. Clin Gastroenterol Hepatol, 2021, 19(8): 1723-1725. DOI: 10.1016/j.cgh.2020.08.063.
[21]	Cheng R T, Wang L, Le S L, et al. A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease[J]. Nat Commun, 2022, 13(1): 2555. DOI: 10.1038/s41467-022-29968-0.
[22]	Zhang H J, He J, Pan L L, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial[J]. JAMA Intern Med, 2016, 176(8): 1074-1082.
[23]	Sabag A, Barr L, Armour M, et al. The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2022, 107(3): 862-881. DOI: 10.1210/clinem/dgab795.
[24]	Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review[J]. J Hepatol, 2017, 66(1): 142-152. DOI: 10.1016/j.jhep.2016.08.023.
[25]	Houghton D, Thoma C, Hallsworth K, et al. Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial[J]. Clin Gastroenterol Hepatol, 2017, 15(1): 96-102.e3. DOI: 10.1016/j.cgh.2016.07.031.
[26]	Shojaee-Moradie F, Cuthbertson D J, Barrett M, et al. Exercise training reduces liver fat and increases rates of VLDL clearance but not VLDL production in NAFLD[J]. J Clin Endocrinol Metab, 2016, 101(11): 4219-4228. DOI: 10.1210/jc.2016-2353.
[27]	Sabag A, Little J P, Johnson N A. Low-volume high-intensity interval training for cardiometabolic health[J]. J Physiol, 2022, 600(5): 1013-1026. DOI: 10.1113/JP281210.
[28]	Motiani K K, Savolainen A M, Toivanen J, et al. Effects of short-term sprint interval and moderate-intensity continuous training on liver fat content, lipoprotein profile, and substrate uptake: a randomized trial[J]. J Appl Physiol, 2019, 126(6): 1756-1768.
[29]	Williams P T. Physical fitness and activity as separate heart disease risk factors: a meta-analysis[J]. Med Sci Sports Exerc, 2001, 33(5): 754-761. DOI: 10.1097/00005768-200105000-00012.
[30]	Green D J, Maiorana A, O'Driscoll G, et al. Effect of exercise training on endothelium-derived nitric oxide function in humans[J]. J Physiol, 2004, 561(Pt 1): 1-25. DOI: 10.1113/jphysiol.2004.068197.
[31]	Fernández T, Viñuela M, Vidal C, et al. Lifestyle changes in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. PLoS One, 2022, 17(2): e0263931.
[32]	Gonzalez A, Valero-Breton M, Huerta-Salgado C, et al. Impact of exercise training on the sarcopenia criteria in non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Eur J Transl Myol, 2021, 31(1): 9630. DOI: 10.4081/ejtm.2021.9630.
[33]	Patel A V, Friedenreich C M, Moore S C, et al. American college of sports medicine roundtable report on physical activity, sedentary behavior, and cancer prevention and control[J]. Med Sci Sports Exerc, 2019, 51(11): 2391-2402. DOI: 10.1249/MSS.0000000000002117.
[34]	Stine J G, Schreibman I R, Faust A J, et al. NASHFit: a randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH[J]. Hepatology, 2022, 76(1): 172-185.
[35]	Babu A F, Csader S, Lok J, et al. Positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters: a systematic review and meta-analysis[J]. Nutrients, 2021, 13(9): 3135. DOI: 10.3390/nu13093135.
[36]	Pugh C A, Sprung V S, Jones H, et al. Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease[J]. Int J Obes, 2016, 40(12): 1927-1930.
[37]	O'Gorman P, Monaghan A, Mcgrath M, et al. Determinants of physical activity engagement in patients with nonalcoholic fatty liver disease: the need for an individualized approach to lifestyle interventions[J]. Phys Ther, 2021, 101(2): pzaa195. DOI: 10.1093/ptj/pzaa195.
[38]	Glass O, Liu D, Bechard E, et al. Perceptions of exercise and its challenges in patients with nonalcoholic fatty liver disease: a survey-based study[J]. Hepatol Commun, 2022, 6(2): 334-344.
[39]	程经纬, 乔军军, 尹振, 等. 《身体活动、心肺适能和心血管健康:美国预防心脏病学会临床实践声明》解读[J]. 中国循证医学杂志, 2024, 24(2): 220-227. DOI: 10.7507/1672-2531.202309008.
[40]	李勃深, 杨军, 王芃, 等. 高原运动效能降低及防治措施[J]. 中南大学学报(医学版), 2023, 48(10): 1464-1478. DOI: 10.11817/j.issn.1672-7347.2023.230074.
[41]	Mccubbin A J, Allanson B A, Caldwell Odgers J N, et al. Sports dietitians Australia position statement: nutrition for exercise in hot environments[J]. Int J Sport Nutr Exerc Metab, 2020, 30(1): 83-98.
[42]	Michael Jett D, Adams K J, Stamford B A. Cold exposure and exercise metabolism[J]. Sports Med, 2006, 36(8): 643-656.
[43]	Hasegawa J, Suzuki H, Yamauchi T. Effect of a lower limb strength training programme on physical activity during the snowy season among community-dwelling elderly individuals[J]. Ann Hum Biol, 2019, 46(4): 323-329. DOI: 10.1080/03014460.2019.1641222.

运动在代谢相关脂肪性肝病管理中的作用：美国运动医学会和澳大利亚运动与体育科学学会国际专家共识解读

The Role of Exercise in the Management of Metabolic-associated Fatty Liver Disease: Interpretation of the International Expert Consensus of ACSM and ESSA

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 43

相关文章 15

编辑推荐

Metrics

留言

[1]	阮何静, 赵文, 李龙灿, 赵久法, 李冬冬. 帕金蛋白在代谢相关脂肪性肝病中的潜在非经典功能及治疗展望[J]. 中国全科医学, 2026, 29(23): 3268-3274.
[2]	张文政, 张红灵. 心脏代谢指数与社区人群老年代谢相关脂肪性肝病患者发生高血压的相关性：一项前瞻性队列研究[J]. 中国全科医学, 2026, 29(23): 3261-3267.
[3]	黄敏杉, 陈杭, 李丽娅, 杨太明, 陈丽芳, 李申超, 任丽, 王卉, 李明珂, 王仙梅, 王达, 万盈, 何昱乐, 周青青, 李钰, 李梦唯, 陆丽红, 罗一凡, 马岚青. 云南多地区普通人群对代谢相关脂肪性肝病的认知现状调查及影响因素研究[J]. 中国全科医学, 2026, 29(17): 2347-2353.
[4]	中国营养学会肥胖防控分会. 中国肥胖行为与生活方式干预指南[J]. 中国全科医学, 2026, 29(16): 2113-2139.
[5]	陈章, 邱珊娇, 李安春, 何智光, 黄文静. 澳大利亚全科医生学会《全科医学的预防活动指南》解读与讨论：工作人群身体活动健康促进与全科实践[J]. 中国全科医学, 2026, 29(13): 1645-1648.
[6]	李春莲, 张颖, 郭铭钊, 何美忱, 徐玲玲, 王永晨. 全科医生开具医疗运动处方促进体医融合[J]. 中国全科医学, 2026, 29(12): 1618-1623.
[7]	陈小龙, 金晶, 华佳禄, 栗玉玉, 潘有加, 潘奇, 涂春景, 王平. 预防大学生肥胖的24 h活动行为最佳时间组合研究[J]. 中国全科医学, 2026, 29(12): 1525-1532.
[8]	景涛, 邱晓荣, 李申森, 刘嘉炜, 祝敬优, 王雪倩, 孙新园, 王侃, 曹彦俊, 季烨林凡, 柏玉洁. 新版明目功运动处方对大学生视疲劳的干预疗效研究[J]. 中国全科医学, 2026, 29(06): 752-759.
[9]	项天乐, 周娜, 李芳, 曹梅娟. 儿童24 h活动行为测评方法研究进展[J]. 中国全科医学, 2026, 29(06): 760-766.
[10]	冯展鹏, 谭思洁, 郭振, 曹立全. 24 h活动行为对青少年代谢综合征的成分等时替代效益研究[J]. 中国全科医学, 2026, 29(03): 325-330.
[11]	张颖, 杨梓钰, 刘力滴, 廖晓阳, 贾禹, 沈灿, 杨荣. 美国运动医学会《成人体力活动与超重、肥胖共识声明》解读[J]. 中国全科医学, 2026, 29(03): 293-298.
[12]	郑华涛, 王世强, 李丹, 杨鄂, 罗丹, 赖雨, 马仁涛. 老年人身体活动变化轨迹与衰弱的关联研究[J]. 中国全科医学, 2026, 29(03): 316-324.
[13]	范学明, 杨宁宁, 郑症, 吴玉梅, 王祺. 2型糖尿病合并代谢相关脂肪性肝病患者微血管病变发生的相关因素分析及预测价值研究[J]. 中国全科医学, 2025, 28(36): 4578-4585.
[14]	张颖, 廖晓阳, 杨寒飞, 余泳君, 刘力滴, 贾禹, 沈灿, 李霄, 黄传应, 杨荣. 2024年《国际高血压学会立场文件：血压测量与报告技术创新》解读及对中国的启示[J]. 中国全科医学, 2025, 28(36): 4541-4549.
[15]	阳坚, 吴传安, 周海蓉, 田峰, 迟春花. 三酰甘油葡萄糖-体质指数对2型糖尿病合并代谢相关脂肪性肝病的诊断价值研究[J]. 中国全科医学, 2025, 28(32): 4075-4081.